157 results about "Recombinant vaccines" patented technology

The invention provides a monoclonal antibody capable of recognizing a recombinant EGF-CRM197 vaccine and a preparation method thereof, on the basis of researching, developing and preparing the recombinant EGF-CRM197 vaccine, after the recombinant EGF-CRM197 vaccine is further immunized and inoculated to a mouse, mouse spleen cells and mouse myeloma cells are fused, and the monoclonal antibody capable of recognizing the recombinant EGF-CRM197 vaccine is obtained. And screening a hybridoma cell strain which generates a specific monoclonal antibody for recognizing the recombinant EGF-CRM197 vaccine, and sequencing to obtain an antibody sequence. After the hybridoma cells are cultured in a mouse body, the monoclonal antibody for recognizing the recombinant EGF-CRM197 vaccine can be prepared in vitro through methods of chromatographic purification and the like. The method can be used for detecting the release titer of the recombinant EGF-CRM197 vaccine and evaluating the immune efficacy after the recombinant EGF-CRM197 vaccine is immunized.

The invention discloses a recombinant HVT for co-expressing an H9 subtype AIV HA gene, an IBV S gene and an IBDV VP2 gene and application of the recombinant HVT, and belongs to the technical field of medicine or veterinary medicine. The recombinant HVT is a recombinant HVT vaccine strain H30201 for co-expressing the H9 subtype AIV HA gene, the IBV S gene and the IBDV VP2 gene, which is obtained by inserting an expression cassette containing the H9 subtype AIV HA gene and the QX type IBV S gene between 95322-95323 nucleotides of an HVT FC126 strain and inserting an expression cassette containing the IBDV classic virulent strain VP2 gene between 112071-112088 nucleotides of an HVT genome at the same time through virus rescue. The invention also provides application of the recombinant HVT vaccine strain in preparation of vaccines for H9 subtype avian influenza, infectious bronchitis and infectious bursal disease.

The invention discloses a Newcastle disease vaccine strain with high antibody escape ability and a modification method thereof, the cell strain is preserved in China General Microbiological Culture Collection Center on January 19, 2024, the address of the preservation unit is CGMCC No.45870, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the classification name of the strain is Newcastle disease virus strain. The recombinant NDV vaccine strain has the same antigen site as the current NDV gene VII type epidemic strain and has the efficient proliferation efficiency superior to that of a classical vaccine strain La Sota, the thermal stability of the NDV vaccine strain is improved by the constructed recombinant vaccine strain, and the cost of vaccine cold-chain transportation is reduced.

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and / or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention relates to the technical field of immunotherapy, in particular to a regulatory protein recombinant vaccine and application thereof in pulmonary fibrosis treatment. The vaccine contains polypeptide of amphiregulin antigen epitopes, and the amino acid sequence of the vaccine is shown as SEQ ID No. 1. A research result shows that the recombinant vaccine can effectively induce generation of a specific antibody aiming at the AREG protein in a mouse body, so that secretion of the AREG protein and activation of downstream receptors of the AREG protein in the pulmonary fibrosis process are inhibited. By reducing collagen deposition in lung tissue and reducing tissue structure damage, the recombinant vaccine significantly reduces gene expression of fibrosis-related protein, recovers lung functions of pulmonary fibrosis model mice, and inhibits further development of diseases. In addition, the recombinant vaccine can be administered in an aerosol inhalation mode, and has broad-spectrum, efficient and long-term stable expression and good safety. The invention provides a brand-new targeted therapy means for clinical prevention and treatment of pulmonary fibrosis, and shows a wide application prospect.

The invention provides an L protein mutated recombinant foot-and-mouth disease virus strain and application thereof in vaccine preparation, and belongs to the technical field of biological medicine. Firstly, it is found that overexpression of CISD2 protein in host cells can inhibit FMDV replication, and an inhibition mechanism is analyzed, specifically, the CISD2 inhibits FMDV replication by inhibiting expression of L protein, especially inducing degradation of the L protein through a proteasome pathway. The invention also identifies a key site for degrading the L protein by the CISD2 protein, the recombinant foot-and-mouth disease virus with the mutated key amino acid site of the L protein is successfully constructed and rescued by introducing amino acid mutation of the key site into the L protein by utilizing a reverse genetic technology, the capabilities of degrading the L protein and inhibiting FMDV replication by the CISD2 protein are eliminated, the virus titer is improved, and the recombinant foot-and-mouth disease virus can be used for preparing the recombinant foot-and-mouth disease virus with the mutated key amino acid site of the L protein. The strain has good production performance and can be used for preparing recombinant foot-and-mouth disease virus strains and recombinant vaccine strains.

Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The present invention relates to a recombinant vaccine comprising a PIV5-based viral expression vector with a genetic insert, and methods of producing and using the same. The recombinant vaccine comprises a modified bacterial or viral antigen to increase expression of the antigen on the surface of cells (AOS) to increase immunogenicity to the antigen.

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a deadly global disease. Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases.

The use of anti-HPV immunogens and nucleic acid molecules encoding them for the treatment and prevention of RRP is disclosed.SOLUTION: Pharmaceutical compositions, recombinant vaccines comprising the DNA plasmids, and live attenuated vaccines are disclosed, as well as methods of inducing an immune response to treat or prevent RRP.SELECTED DRAWING: Figure 1

The present invention provides a monoclonal antibody that recognizes a recombinant EGF-CRM197 vaccine and a preparation method thereof. Based on the research and development and preparation of a recombinant EGF-CRM197 vaccine, the present invention further immunizes mice with the recombinant EGF-CRM197 vaccine, fuses the mouse spleen cells with mouse myeloma cells, screens and produces a hybridoma cell line of specific monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine, and obtains the antibody sequence after sequencing. After the hybridoma cells are cultured in mice, monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine can be prepared in vitro by methods such as chromatography purification. The present invention can be used for the release potency detection of the recombinant EGF-CRM197 vaccine and for evaluating the immune efficacy after immunization with the recombinant EGF-CRM197 vaccine.

The invention discloses a porcine pseudorabies virus strain, a construction method of a reverse genetic manipulation platform of the porcine pseudorabies virus strain, a recombinant porcine pseudorabies virus and application of the recombinant porcine pseudorabies virus, the porcine pseudorabies virus strain is a porcine pseudorabies virus PRV-HL-2021 strain, the preservation number of the porcine pseudorabies virus strain is CGMCC No.46094, and the porcine pseudorabies virus strain is preserved in China General Microbiological Culture Collection Center on July 29, 2024. The invention provides a porcine pseudorabies virus strain, and constructs a college reverse genetic manipulation platform for the porcine pseudorabies virus strain, so that the porcine pseudorabies virus gene can be quickly and accurately modified, the function of the porcine pseudorabies virus gene can be researched, and a new live virus vector is developed for the research of recombinant vaccines.

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

The application belongs to the field of vaccines and genetic engineering technology, and relates to an H3N2 canine influenza recombinant virus strain and application thereof. Specifically, the application relates to a recombinant canine influenza vaccine strain which is obtained by recombination of the following genes: an HA gene, an NA gene, a PB1 gene, a PB2 gene, a PA gene, an NP gene, an M gene and an NS gene; wherein the sequence of the HA gene is shown as SEQ ID NO:1; and / or the sequence of the NA gene is shown as SEQ ID NO:2. The application also relates to an H3N2 canine influenza recombinant vaccine and a method for preparing the H3N2 canine influenza recombinant vaccine.

The present invention relates to the field of biomedical technologies, and discloses a long-acting and stable recombinant RSV vaccine based on glycan modification and phase change materials. The vaccine comprises the following components in parts by mass: RSV F protein modified with dynamic glycans: 1 part; multi-stage phase change materials: 3-5 parts, and the multi-stage phase change materials are composed of polyethylene glycol-stearate and lauric acid-cholesterol complex, wherein the mass ratio of polyethylene glycol-stearate to lauric acid-cholesterol is 2-3:1; TLR9 agonist: 0.05-0.15 part; STING agonist: 0.02-0.08 part; amphiphilic block copolymer PLGA-PEG-PLL: 0.5-1.5 parts. The present invention solves the problems of easy inactivation, poor targeting and insufficient immunogenicity of traditional vaccines, is applicable to the prevention and treatment of viral infectious diseases, and has the application potential for large-scale production.

This invention relates to a fusion protein, immunogenic composition, and recombinant vaccine for the prevention of Escherichia coli infection. The invention provides a novel target, PstS, for Escherichia coli vaccine design. Starting from the tertiary structure of PstS and YidR proteins, and combining immunoepitaxes, stable domains of PstS and YidR proteins and their variants are ultimately screened, leading to the construction of a fusion protein. Both the PstS monoantigen protein molecule and the PstS-YidR fusion protein molecule of this invention exhibit good immunogenicity, can reduce tissue lesions caused by Escherichia coli infection, and demonstrate high efficacy in preventing Escherichia coli infection, showing broad application prospects.

The invention relates to a novel fusion protein for preventing and treating mycoplasma bovis infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion protein molecular architecture, which comprises fusion proteins coded by two genes of Bmp and FBA, or fusion proteins coded by three genes of EF-Tu, DnaK and EF-G, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The fusion molecule has good immunogenicity, provides an effective immune protection effect, can eliminate bovine mycoplasma colonization in part of individuals, can be used for preventing and treating bovine mycoplasma infection diseases, and has a wide application prospect in animal husbandry.

The present invention relates to a fusion protein, immunogenic composition, recombinant vaccine, and molecular architecture design and application, etc., for the prevention of Streptococcus Pneumoniae infection. The present invention starts from the protein molecular tertiary structures of ply and PhtD, and via creatively screening, the C-terminal domain of ply protein and the N-terminal domain of phtD protein are finally selected to construct a fusion protein, and the elements such as Fc domain and STABILON are further added. The fusion protein molecule of the present invention can weaken tissue lesions caused by Streptococcus Pneumoniae infection, has good immunogenicity, has an effective preventive and immunoprotective effect, and efficiently prevents Streptococcus Pneumoniae infection. The immunogenic composition, fusion protein, and recombinant vaccine for preventing Streptococcus Pneumoniae infection of the present invention have broad application prospects.

The invention relates to a novel immunogenic composition for preventing and treating pseudomonas aeruginosa infection, a fusion protein, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion molecular architecture, which comprises a fusion protein A coded by three genes of EF-Tu, DnaK and EF-G, or a fusion protein B coded by two genes of PcrV and PilA, or a combination of the fusion protein A and the fusion protein B, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The invention finds that the novel fusion molecule has good immunogenicity, can provide an effective immune protection effect, remarkably inhibits colonization of pseudomonas aeruginosa, and has a wide application prospect.

The invention relates to a fusion protein for preventing klebsiella pneumoniae infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design, application and the like. The invention provides a vaccine for independently expressing a PstS antigen and a vaccine for expressing a fusion protein of YidR-PstS or PstS-YidR, and elements such as an Fc structural domain and STABILON are added. The invention also provides corresponding recombinant nucleic acid, a gene expression cassette, a vector, a host cell, a pharmaceutical composition, a vaccine, application and the like. The vaccine can weaken tissue lesions caused by klebsiella pneumoniae infection, has good immunogenicity, plays effective prevention and immune protection roles, efficiently prevents klebsiella pneumoniae infection, and has wide application prospects.

The application provides a standard plasmid for detecting the copy number of exogenous genes of a recombinant CVA10 vaccine, and a preparation method and application thereof. The standard plasmid of the application comprises an endogenous gene MOX fragment SEQ ID No. 1, an exogenous gene P1 fragment SEQ ID No. 2 and an exogenous gene 3CD fragment SEQ ID No. 3 which are connected in series in a cloning vector. The application constructs the standard plasmid, adopts Taqman probe-fluorescence quantitative PCR method, and simply, quickly, absolutely quantitatively and accurately analyzes the copy number of inserted exogenous genes, so that the detection time of the determination of the copy number of exogenous genes of the recombinant CVA10 vaccine is effectively shortened, repeated operation is facilitated, and the determination of the copy number of exogenous genes of the recombinant CVA10 vaccine based on the Hansenula platform and the verification of the genetic stability of the exogenous genes of the recombinant CVA10 vaccine have a wide application prospect.

The invention relates to a fusion protein for preventing salmonella infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design, application and the like. According to the invention, three fusion proteins, namely PstS-LpfB, PstS-YidR and LpfB-SinH, which can be smoothly expressed in eukaryotic cells are selected to carry out animal immune experiments, so that the protection effect is verified. The invention finds that fusion protein molecules such as PstS-LpfB and the like can weaken tissue lesions caused by salmonella infection, have good immunogenicity, play a role in effective prevention and immune protection, efficiently prevent salmonella infection and have wide application prospects.

The application discloses a CMV virus-like particle for producing a VLP recombinant vaccine and a preparation method thereof, the CMV virus-like particle is obtained by cloning a C-terminal G4SLPETG modified plant virus cucumber mosaic virus CMV capsid gene into a prokaryotic expression vector to obtain a recombinant expression vector, the recombinant expression vector is transfected into E. coli BL21 (DE3), and expression is obtained through the recombinant E. coli BL21 (DE3); and the amino acid sequence of the C-terminal G4SLPETG modified CMV is SEQ ID NO. 1. Test proves that the recombinant strain constructed by the application is stable to expression of an exogenous protein. The recombinant protein expressed by the application is used for preparing a virus-like particle for antigen coupling, the coupling efficiency is high, the antigen purity is high, the safety is good, the virus-like particle is not pathogenic to mice and other animals, and the safety evaluation is easy.

The present application relates to the fusion protein, immunogenic composition, recombinant vaccine and application for preventing acinetobacter baumannii infection, etc. The present application screens and obtains four groups of antigen combination fusion protein mRNA vaccines of AdeK-LolB, Omp22-HphA, Omp22-LolB and CsuE-CsuAB, which show excellent effects in the mouse acinetobacter baumannii infection model. Compared with the nucleic acid vaccine encoded by the Omp22-Omp38 fusion protein known in the prior art and having excellent effects itself, the nucleic acid vaccine has better immunization effects and protective effects for preventing acinetobacter baumannii infection in reducing acinetobacter baumannii colonization and reducing the degree of lesions caused by infection, and has a wide application prospect.

The present invention relates to an immunogenic composition against Neisseria meningitidis serogroup B in liquid form and a reconstituted vaccine against Neisseria meningitidis serogroups A, B, C, W135, and Y comprising this liquid composition. Also provided are kits and methods for the prevention and treatment of Neisseria meningitidis infections and diseases using the immunogenic composition or the reconstituted vaccine.

The invention relates to a fusion protein, an immunogenic composition, a recombinant vaccine and the like for preventing Escherichia coli infection. The invention provides a new target PstS for Escherichia coli vaccine design, starting from a protein molecule tertiary structure of PstS and YidR, combining with immune epitopes and the like, finally screening to obtain a PstS protein, a YidR protein and stable structural domains of variants of the PstS protein and the YidR protein, and constructing to obtain a fusion protein. The PstS single antigen protein molecule or the PstS-YidR fusion protein molecule provided by the invention has good immunogenicity, can weaken tissue lesions caused by Escherichia coli infection, has good immunogenicity, can efficiently prevent Escherichia coli infection, and has a wide application prospect.

The invention discloses a recombinant I-type herpes simplex virus vaccine and application thereof, and belongs to the technical field of vaccines. In particular to a fusion protein which is composed of an antigen molecule gD1, a human immunoglobulin antibody Fc structural domain and a human IgG1 hinge region fragment, the amino acid sequence of the antigen molecule gD1 is shown as SEQ ID NO.6, and a recombinant vaccine is constructed. The recombinant vaccine fuses a virus antigen, an immune globulin heavy chain Fc structural domain and a human IgG1 hinge region fragment, has better capability of being combined with a receptor on the surface of an antigen presenting cell, can activate specific CD4 + T and CD8 + T cells, generates high-titer antibody titer and specific cellular immunity, and can be used for preparing a high-titer antibody. The vaccine can prevent infection and / or reinfection of the herpes simplex type I virus.